Checkpoint Therapeutics Files 2024 10-K
| Field | Detail |
|---|---|
| Company | Checkpoint Therapeutics, Inc. |
| Form Type | 10-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, warrants
TL;DR
Checkpoint TX filed its 2024 10-K. Financials look stable, but watch warrant liabilities.
AI Summary
Checkpoint Therapeutics, Inc. filed its 2024 10-K on March 28, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing details the company's business operations, financial condition, and risk factors. Key financial data includes figures related to warrant liabilities and revenue recognition, with specific values such as $5.00, $3.35, and $2.821 appearing in the context of financial measurements.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Checkpoint Therapeutics' financial health and strategic direction for the past fiscal year, crucial for understanding its current market position and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Checkpoint Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- $5.00 — Financial Measurement (Indicates a specific value related to financial reporting, potentially warrant liabilities or other fair value inputs.)
- $3.35 — Financial Measurement (Another value from financial reporting, likely related to fair value measurements.)
- $2.821 — Financial Measurement (A precise financial figure, possibly a component of asset or liability valuation.)
- 2024-12-31 — Fiscal Year End (Defines the period covered by the financial statements in the 10-K.)
- 2025-03-28 — Filing Date (The date the 10-K was officially submitted to the SEC.)
Key Players & Entities
- Checkpoint Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-28 (date) — Filing date
- $5.00 (dollar_amount) — Financial measurement value
- $3.35 (dollar_amount) — Financial measurement value
- $2.821 (dollar_amount) — Financial measurement value
FAQ
What was Checkpoint Therapeutics' total revenue for the fiscal year ending December 31, 2024?
The provided snippet does not explicitly state the total revenue for the fiscal year ending December 31, 2024, but it references the 'Revenues' standard under FASB.
What is the significance of the 'GainLossOnCommonStockWarrantLiabilities' mentioned in the filing?
The filing includes links to 'GainLossOnCommonStockWarrantLiabilities', indicating that changes in the fair value of common stock warrant liabilities are a reported financial item for Checkpoint Therapeutics.
What are the key inputs used for valuing the Placement Agent Warrants as of December 31, 2024?
As of December 31, 2024, the fair value inputs for Placement Agent Warrants included Share Price, Risk-Free Interest Rate, Price Volatility, and Expected Term, all categorized under Fair Value Inputs Level 3.
When was Checkpoint Therapeutics, Inc. incorporated?
Checkpoint Therapeutics, Inc. was incorporated in Delaware (DE).
What is the business address and phone number for Checkpoint Therapeutics, Inc.?
The business address is 95 Sawyer Road, Suite 110, Waltham, MA 02453, and the business phone number is 781-652-4500.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 28, 2025 regarding Checkpoint Therapeutics, Inc..